Search

Your search keyword '"Maria Luisa Gonzalez Dieguez"' showing total 9 results
Start Over Author "Maria Luisa Gonzalez Dieguez" Topic medicine
9 results on '"Maria Luisa Gonzalez Dieguez"'

1. FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study

Author

Mario Cristobal Romero, Matthias Pinter, Maria Margarita Anders, Wörns Marcus, Vincenzo Mazzaferro, Pietro Lampertico, Aballay Soteras Gabriel Alejandro, Maria Varela, Federico Piñero, Maria Reig, Sherrie Bhoori, Federica Invernizzi, Massimo De Giorgio, Carolin Czauderna, Maria Jose Blanco Rodríguez, Gonzalo Crespo, Gerda Elisabeth Villadsen, Massimo Lavarone, Arndt Weinmann, Matteo Angelo Manini, Maria Luisa Gonzalez Dieguez, Marco Sanduzzi Zamparelli, Miguel Fraile, Jordi Bruix, Maria Francesca Donato, Hélène Regnault, and Giuliana Amaddeo

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Liver transplantation, chemistry.chemical_compound, chemistry, Regorafenib, Internal medicine, Medicine, business, medicine.drug
Published
2019

2. SAT-489-Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma and high comorbidity

Author

Paola Rueda, Carmen Álvarez-Navascués, Maria Varela, Ana Lara Gómez, Alicia Mesa, Andrés Castaño-García, V. Cadahía-Rodrigo, María Torner, Maria Luisa Gonzalez Dieguez, Manuel Rodríguez, and Amador Prieto

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Thermal ablation, Medicine, In patient, business, medicine.disease, Comorbidity, Gastroenterology
Published
2019

3. Factors implicated in the risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis due to HCV Implications of Sustained Virological Response (SVR)

Author

M. Fraile, M. Varela, Ana Lara Gómez, V. Cadahía-Rodrigo, M. Rodríguez, Carmen Álvarez-Navascués, A. Castaño, María Torner, and Maria Luisa Gonzalez Dieguez

Subjects
Virological response, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2018

4. SAT-460-Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis

Author

Maria Varela, María Torner, Maria Luisa Gonzalez Dieguez, Carmen Álvarez-Navascués, V. Cadahía-Rodrigo, Ana Lara Gómez, and Manuel Rodríguez

Subjects
Virological response, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, medicine, In patient, Alpha-fetoprotein, medicine.disease, business, Gastroenterology
Published
2019

6. FRI-022-Characteristics of autoimmune hepatitis with acute presentation

Author

Maria Varela, Carmen Álvarez-Navascués, V. Cadahía-Rodrigo, Ana Lara Gómez, Andrés Castaño-García, Manuel Rodríguez, María Torner, and Maria Luisa Gonzalez Dieguez

Subjects
Hepatology, business.industry, Immunology, medicine, Autoimmune hepatitis, Presentation (obstetrics), medicine.disease, business
Published
2019

7. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort

Author

J.I. Herrero, Sonia Pascual Bartolome, I. Fernandez Vazquez, Jose Antonio Pons Miñano, G. Sanchez Antolin, Emilio Fabrega Garcia, Esther Molina, I. Narvaez Rodriguez, Ana Arencibia, Mario Romero Cristobal, M. Testillano, Anselmo J. Otero, Martín Prieto, Xavier Xiol, Sara Lorente, Luis Castells, Valentín Cuervas-Mons, José Luis Montero, María Dolores Espinosa, Maria Luisa Gonzalez Dieguez, Juan Manuel Pascasio, and María-Carlota Londoño

Subjects
Simeprevir, Liver Cirrhosis, Male, medicine.medical_specialty, Sofosbuvir, Genotype, Hepatitis C virus, medicine.medical_treatment, Hepacivirus, Liver transplantation, medicine.disease_cause, Gastroenterology, Antiviral Agents, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Internal medicine, Ribavirin, medicine, Humans, Retrospective Studies, Hepatitis, Transplantation, medicine.diagnostic_test, business.industry, Hepatitis C, Chronic, Middle Aged, medicine.disease, Liver Transplantation, Drug Combinations, Treatment Outcome, Spain, 030220 oncology & carcinogenesis, Liver biopsy, Immunology, 030211 gastroenterology & hepatology, Surgery, Drug Therapy, Combination, Patient Safety, business, medicine.drug
Abstract

Background Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of 2nd-generation direct-acting antivirals (DAAs), and more data are needed to help guide treatment decisions. We still have even fewer data concerning liver transplant patients. Simeprevir (SIM) and sofosbuvir (SOF) combination is useful to treat this genotype. The aim of this study was to know the efficacy and safety of the combination SIM + SOF ± ribavirin (RBV) in a group of liver transplant patients with HCV genotype 4 infection in Spain in real life. Methods This was a multicenter retrospective study, including 28 HCV genotype 4 patients from 11 liver transplant centers who were treated with SIM + SOF ± RBV. We included in the analysis demographic, clinical, and virologic data and details of serious adverse events (SAEs), including mortality rate 6 months after treatment. Results All patients were male, mean age 52 ± 9.43 years, and 50% were IL28B CT and 37.5% TT; 46.42% of them were pretreated and 76.9 were null responders. Fibrosis stage 4 was found in 38.7% of patients; in 67.8% of those cases the diagnosis of fibrosis was made with the use of Fibroscan, in 21.4% by liver biopsy. The average Fibroscan was 13.86 KPa. The average Model for End-Stage Liver Disease (MELD) score of cirrhotic patients was 10.9 and the Child-Pugh score was A in 70%, B in 20%, and C in 10%. We included RBV in 75% of patients, and treatment duration was 12 weeks in all patients. The sustained virologic response at week 12 (SVR12) was 95.23%. There were no discontinuations due to SAEs, but the mortality rate at 6 months after treatment was 7.14%. All deceased patients were cirrhotic, Child C, and with an average MELD score of 20. Conclusions The combination SIM + SOF ± RBV to treat HCV genotype 4 in liver transplant patients is an option with high rates of SVR12 and very safe, similarly to genotype 1. There was no treatment-related mortality, but when it is administered in advanced stages of fibrosis it may not be enough to prevent mortality associated with cirrhotic hepatitis C recurrence after transplantation.

Published
2016

8. Analysis of the influence of alcohol abstinence on the risk of developing hepatocellular carcinoma (HCC) in patients with alcoholic liver cirrhosis (ALC)

Author

María Torner, Maria Luisa Gonzalez Dieguez, Carmen Álvarez-Navascués, M. Rodríguez, Ana Lara Gómez, Andrés Castaño-García, M. Varela, M. Fraile, and V. Cadahía-Rodrigo

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Medicine, In patient, business, medicine.disease, Gastroenterology, Alcohol Abstinence
Published
2018

9. Usefulness of liver stiffness measurement by transient elastography for predicting complications in patients with alcoholic liver disease

Author

M. Fraile, Carmen Álvarez-Navascués, Andrés Castaño-García, María Torner, Maria Luisa Gonzalez Dieguez, Ana Lara Gómez, M. Varela, M. Rodríguez, B. Redondo, V. Cadahía-Rodrigo, and P. Alonso

Subjects
medicine.medical_specialty, Alcoholic liver disease, Hepatology, business.industry, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Liver stiffness, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, In patient, business, Transient elastography
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results